Vitaliana DE Sanctis1, Alice DI Rocco2, Maria Christina Cox3, Maurizio Valeriani1, Francesca Perrone Congedi1, Dimitri Anzellini1, Maria Massaro1, Gianluca Vullo4, Giuseppe Facondo1, Flavia DE Giacomo1, Marco Alfò5, Daniela Prosperi6, Patrizia Pizzichini6, Sabrina Pelliccia3, Agostino Tafuri3,7, Maurizio Martelli2, Mattia Falchetto Osti1. 1. Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy. 2. Department of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Rome, Italy. 3. Hematology Institute, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy. 4. Radiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy gianluca.vullo@uniroma1.it. 5. Department of Statistical Sciences, Sapienza University of Rome, Rome, Italy. 6. Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Sapienza University of Rome, Rome, Italy. 7. Department of Clinic and Molecular Medicine and Hematology, Sapienza, University of Rome and S. Andrea University Hospital of Rome, Rome, Italy.
Abstract
AIM: To evaluate the efficacy of residual site radiation therapy (RSRT) on local control (LC), progression-free (PFS) and overall (OS) survival in patients with primary mediastinal lymphoma (PMBCL), following rituximab and chemotherapy treatment (ICHT). PATIENTS AND METHODS: The study included 34 patients with PMBCL treated between 2006 and 2014 with ICHT with/without autologous stem cell transplantation and RSRT. Between the end of ICHT/stem cell transplantation and RSRT, patients were evaluated with 18F-fluorodeoxyglucose positron-emission tomography. The gross tumor volume included morphological mediastinal residual disease after ICHT/SCT. The percentage of LC, PFS and OS were assessed. RESULTS: All patients received RSRT with a median dose of 30 Gy. Median follow-up was 82 months. One patient out of 34 (3%) showed progressive disease 9 months from diagnosis. The 10-year PFS and OS were 97% and 97% respectively. CONCLUSION: RSRT in patients with PMBCL treated with ICHT did not impact unfavorably on LC and patient survival. Copyright
AIM: To evaluate the efficacy of residual site radiation therapy (RSRT) on local control (LC), progression-free (PFS) and overall (OS) survival in patients with primary mediastinal lymphoma (PMBCL), following rituximab and chemotherapy treatment (ICHT). PATIENTS AND METHODS: The study included 34 patients with PMBCL treated between 2006 and 2014 with ICHT with/without autologous stem cell transplantation and RSRT. Between the end of ICHT/stem cell transplantation and RSRT, patients were evaluated with 18F-fluorodeoxyglucose positron-emission tomography. The gross tumor volume included morphological mediastinal residual disease after ICHT/SCT. The percentage of LC, PFS and OS were assessed. RESULTS: All patients received RSRT with a median dose of 30 Gy. Median follow-up was 82 months. One patient out of 34 (3%) showed progressive disease 9 months from diagnosis. The 10-year PFS and OS were 97% and 97% respectively. CONCLUSION: RSRT in patients with PMBCL treated with ICHT did not impact unfavorably on LC and patient survival. Copyright
Authors: Paul A Hamlin; Carol S Portlock; David J Straus; Ariela Noy; Andrew Singer; Steven M Horwitz; Owen A Oconnor; Joachim Yahalom; Andrew D Zelenetz; Craig H Moskowitz Journal: Br J Haematol Date: 2005-09 Impact factor: 6.998
Authors: Tithi Biswas; Eva Culakova; Jonathan W Friedberg; Jennifer L Kelly; Sughosh Dhakal; Jane Liesveld; Gordon L Phillips; Louis S Constine Journal: Radiother Oncol Date: 2012-03-05 Impact factor: 6.280
Authors: Lena Specht; Joachim Yahalom; Tim Illidge; Anne Kiil Berthelsen; Louis S Constine; Hans Theodor Eich; Theodore Girinsky; Richard T Hoppe; Peter Mauch; N George Mikhaeel; Andrea Ng Journal: Int J Radiat Oncol Biol Phys Date: 2013-06-18 Impact factor: 7.038
Authors: Louis S Constine; Joachim Yahalom; Andrea K Ng; David C Hodgson; Andrew Wirth; Sarah A Milgrom; N George Mikhaeel; Hans Theodor Eich; Tim Illidge; Umberto Ricardi; Karin Dieckmann; Craig H Moskowitz; Ranjana Advani; Peter M Mauch; Lena Specht; Richard T Hoppe Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-09 Impact factor: 7.038
Authors: Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson Journal: N Engl J Med Date: 2013-04-11 Impact factor: 91.245
Authors: Berthe M P Aleman; John M M Raemaekers; Umberto Tirelli; Roberto Bortolus; Mars B van 't Veer; Marnix L M Lybeert; Jo J Keuning; Patrice Carde; Théodore Girinsky; Richard W M van der Maazen; Radka Tomsic; Marjeta Vovk; Achilles van Hoof; Geertrui Demeestere; Pieternella J Lugtenburg; José Thomas; Wilfried Schroyens; Koenraad De Boeck; Johanna W Baars; Johanna C Kluin-Nelemans; Christian Carrie; Malek Aoudjhane; Dominique Bron; Houchingue Eghbali; Wilma G J M Smit; Jacobus H Meerwaldt; Anton Hagenbeek; Antonella Pinna; Michel Henry-Amar Journal: N Engl J Med Date: 2003-06-12 Impact factor: 91.245